Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Haie Meder, C ^a   Morice, P ^b   Castiglione, M ^c  

^a Department of Radiation Oncology ^*  (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; TOPOTECAN; VINCRISTINE;

ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CLINICAL EXAMINATION; CLINICAL TRIAL; FOLLOW UP; HUMAN; HYSTERECTOMY; METASTASIS; OVARIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR BIOPSY; UTERINE CERVIX CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; META-ANALYSIS AS TOPIC; NEOPLASM METASTASIS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 77954319884     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq162     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. 2002; CA Cancer J Clin 2005(55): 74-108.
2. Anttila A, von Karsa L, Aasmaa A et al. Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009; 15: 2649-2658.
3. Louie KS, de Sanjose S, Diaz M et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 2009; 100: 1191-1197.
4. Hakim AA, Dinh TA. Worldwide impact of the human papillomavirus vaccine. Curr Treat Opt Oncol 2009; 10: 44-53.
5. FIGO committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol Obstet 2009; 105: 103-104.
6. Trimble EL. Cervical cancer state-of-the-clinical-science meeting on pretreatment evaluation and prognostic factors, September 27-28, 2007: proceedings and recommendations. Gynecol Oncol 2009; (114): 145-150.
7. Rockall AG, Sohaib SA, Harisinghani MG et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23: 2813-2821.
8. Magné N, Chargari C, Vicenzi L et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat Rev 2008; 34: 671-681.
9. Gortzak-Uzan L, Jimenez W, Nofech-Mozes S et al. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard? Gynecol Oncol 2010; 116: 28-32.
10. Barbera L, Thomas G. Management of early and locally advanced cervical cancer. Semin Oncol 2009; 36: 155-169.
11. Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 2010; 116: 140-146.
12. Gaducci A, Sartori E, Maggino T et al. The clinical outcome of patients with stage Ia1 and Ia2 squamous cell carcinoma of the uterine cervix: a Cooperation Task Force (CTF) study. Eur J Gynaecol Oncol 2003; 24: 513-516.
13. Gray HJ. Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy. J Natl Compr Canc Netw 2008; 6: 47-52.
14. Landoni F, Maneo A, Colombo A et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350: 535-540.
15. Beiner ME, Covens A. Surgery insight: radical vaginal trachelectomy as a method of fertility reservation for cervical cancer. Nat Clin Pract Oncol 2007; 4: 353-361.
16. Keys HM, Bundy TM, Stehman FB et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 2003; 89: 343-353.
17. Green JA, Kirwan JM, Tierney JF et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 358: 781-786.
18. Lukka H, Hirte H, Fyles A et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer-a meta-analysis. Clin Oncol 2002; 14: 203-212.
19. Vale C, Tierney JF, Stewart LA et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008; 26: 5802-5812.
20. Gonzales Duenas A, Zarba JJ, Alcedo JC et al. A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2009; 27 (18 Suppl): Abstr CRA5507.
21. Thomas G, Shamshad A, Hoebers F et al. Phase III trial to evaluate the efficacy of maintaining haemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008; 108: 317-325.
22. Girinsky T, Rey A, Roche B et al. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993; 27: 1051-1056.
23. Pötter R, Dimopoulos J, Georg P et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 2007; 83: 148-155.
24. Chargari C, Magné N, Dumas I et al. Physics contribution and clinical outcome with 3D MRI-based pulsed dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 2009; 74: 133-139.
25. Neoadjuvant chemotherapy for cervical cancer meta-analysis collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 2003; 39: 2470-2486.
26. Eddy GL, Bundy BN, Creasman WT et al. Treatment of ('bulky') stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol 2007; 106: 362-369.
27. Tzioras S, Pavlidis N, Paraskevaidis E et al. Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and metaanalysis. Cancer Treat Rev 2007; 33: 24-38.
28. Long HJ 3rd, Bundy BN, Grendys EC et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4617-4625.
29. Monk BJ, Sill MW, Mc Meekin DS et al. Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecological Oncology Group study. J Clin Oncol 2009; 27: 4649-4655.
30. Kew FM, Cruickshank DJ. Routine follow-up after treatment for a gynaecological cancer: a survey practice. Int J Gynecol Cancer 2006; 16: 380-384.
31. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol 2008; 66: 10-20.
32. Elit L, Fyles AW, Devries MC et al. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009; 114: 528-535.